SciLifeLab The Svedberg seminar series, Yumeng Mao

Monday, 9 March, 2020

Yumeng Mao 

SciLifeLab Fellow at Uppsala University

Yumeng Mao is supported by the SciLifeLab Fellow Programme to establish a research group on translational cancer immunology at IGP, Uppsala University. Prior to his appointment, he was a full time employee at AstraZeneca Oncology R&D Headquarters in Cambridge, UK, where he led early stage small molecule drug discovery projects. Yumeng received his doctoral and post-doctoral training at the Karolinska Institute under the mentorship of Prof Rolf Kiessling.

Title of the talk: Resistance to PD-1/L1 blockade: Challenges and opportunities on the negative regulatory pathways

Activation of the human immune system through blockade against the programmed cell death protein 1 (PD-1) or its ligand PD-L1 has led to the approval of several innovative medicines for cancer patients. However, 80% of the patients fails to enjoy long-term benefits, probably due to multiple resistance mechanisms in the tumour micro-environment. My group aims to reveal the functional hierarchy and dominant pathways in myeloid cells and cancer cells, in order to reveal novel pathways that can enhance the efficacy of the PD-1/L1 blockage. We have a special focus on rare cancer types with significant unmet medical needs such as childhood neuroblastoma. To achieve this, we will develop and optimise a suite of pre-clinical assays and models using the CRISPR/Cas9-based precise genome editing approach. In a long run, we hope to build an inter-disciplinary framework to achieve data-led hypothesis generation and pathway validation for cancer immunotherapy.

Host: Mia Phillipson